---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006441"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T09:25:17.753195+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioCryst enrolls first patient in proof-of-concept trial for oral Factor D inhibitor BCX10013

## Summary
- First patient enrolled in open-label, multicenter dose-escalation trial of BCX10013 in up to 15 PNH patients.
- Primary endpoints: treatment-emergent AEs, graded lab abnormalities; secondary: LDH, hemoglobin, transfusion-free rate.
- If best-in-class profile confirmed in PNH, company plans to advance to pivotal program in renal complement diseases like IgAN.
- Trial conducted in countries without standard-of-care complement inhibitor therapy; NCT06100900.

## SEC filing metadata
- accession: 0001171843-23-006441
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323006441/0001171843-23-006441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323006441/f8k_102623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006441
- JSON: https://secwatch.observer/filing/0001171843-23-006441.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006441.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.